Minimal toxicity during protein a immunoadsorption treatment of malignant disease: An outpatient therapy

Extracorporeal removal or modulation of circulating immune complexes (CIC) from plasma of animals and humans with malignant disease may be associated with induction of immune‐mediated anti‐tumor responses. Immunoadsorption columns containing heat‐killed and formalin‐fixed Staphylococcus aureus or staphylococcal protein A have been used for this purpose but treatments have often been associated with cardiopulmonary toxicity. Recently, an immunoadsorption device containing highly purified protein A covalently attached to a silica matrix (PROSORBA© column) was used to treat 142 patients with refractory malignancies and 22 of 104 patients evaluated for anti‐tumor response had objectively measurable reduction in tumor burden. In contrast to earlier experience with other devices, the procedures used in this trial were well tolerated and could be performed on an outpatient basis. The most common side effects observed among 1,306 treatments were chills (28% of treatments), low grade fever (28%), and musculoskeletal pain (16%). Side effects were mild to moderate and required no treatment or only symptomatic treatment. Treatment schedules were interrupted due to side effects for only six patients and there were no treatment‐related deaths. Of 64 patients available for long‐term follow‐up evaluation (mean of 11 months), none exhibited evidence of long‐term treatment‐related side effects. None of the patient deaths in that period were associated with short or long‐term treatment‐related side effects. Protein A‐lica (PROSORBA© columns) can be used safely for development of further experimental treatments of malignant disease.

[1]  J. J. Langone.  Immune complex formation enhances the binding of staphylococcal protein A to immunoglobulin G. , 1980, Biochemical and biophysical research communications.

[2]  F. Jones,et al.  Perfusion of canine serum over Staphylococcus aureus Cowan 1: Evidence for release of protein A and changes in specific antibody activity. , 1983, Immunological communications.

[3]  Max H. Myers,et al.  Manual for Staging of Cancer , 1992 .

[4]  M. Viola,et al.  Protein A immunoadsorption in the treatment of malignant disease. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. R. Cooper,et al.  Efficient removal of abnormal immunoglobulin G from the plasma of a multiple myeloma patient description of a new method for treatment of the hyperviscosity syndrome. Description of a new method for treatment of the hyperviscosity syndrome , 1980, Cancer.

[6]  C. Dinarello.  Interleukin-1 and the pathogenesis of the acute-phase response. , 1984, The New England journal of medicine.

[7]  L. Håkansson,et al.  Tumour regression after extracorporeal affinity chromatography of blood plasma across agarose beads containing staphylococcal protein A. , 1984, European journal of cancer & clinical oncology.

[8]  Snyder Hw,et al.  Modulation of immunity in patients with autoimmune disease and cancer treated by extracorporeal immunoadsorption with PROSORBA columns. , 1989 .

[9]  D S Terman,et al.  Antitumor effects of immobilized protein A and staphylococcal products: linkage between toxicity and efficacy, and identification of potential tumoricidal reagents. , 1985, European journal of cancer & clinical oncology.

[10]  D. R. Cooper,et al.  Extracorporeal immunoadsorption of plasma from a metastatic colon carcinoma patient by protein a‐containing nonviable staphylococcus aureus. Clinical, biochemical, serologic, and histologic evaluation of the Patient's response , 1982, Cancer.

[11]  M. Viola,et al.  Protein A immunotherapy in the treatment of cancer: an update. , 1989, Seminars in hematology (Print).

[12]  K. Hellström,et al.  Blocking (suppressor) factors, immune complexes, and extracorporeal immunoadsorption in tumor immunity. , 1985, Contemporary topics in immunobiology.

[13]  M. Apuzzo,et al.  Staphylococcal Protein A column: correlation of mitogenicity of perfused plasma with clinical response. , 1985, Cancer research.

[14]  J. Shields,et al.  Treatment of advanced malignancy with plasma perfused over staphylococcal protein A. , 1983, The Western journal of medicine.

[15]  H. Snyder,et al.  ProsorbaR Treatment Column: A Device that Removes Circulating Immune Complexes (CIC), IgG, and Autoimmune Antibodies From Patient Plasma , 1987 .

[16]  Langone Jj.  Protein A of Staphylococcus aureus and related immunoglobulin receptors produced by streptococci and pneumonococci. , 1982 .

[17]  S. Rosenberg,et al.  NIH conference. New approaches to the immunotherapy of cancer using interleukin-2. , 1988, Annals of internal medicine.

[18]  S W Kessler,et al.  Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interaction of antibody-antigen complexes with protein A. , 1975, Journal of immunology.

[19]  R. Inman,et al.  Binding of immunoglobulin G aggregates and immune complexes in human sera to Staphylococci containing protein A. , 1979, The Journal of clinical investigation.

[20]  T. Phillips,et al.  The pathophysiology of circulating immune complexes: their role in host-tumor interactions and removal by immunoadsorption therapy. , 1985, Contemporary topics in immunobiology.

[21]  D. Chenoweth.  Complement Activation in Extracorporeal Circuits , 1987, Annals of the New York Academy of Sciences.

[22]  R. Miller,et al.  Cardiopulmonary toxicity in patients with breast carcinoma during plasma perfusion over immobilized protein A. Pathophysiology of reaction and attenuating methods. , 1983, The American journal of medicine.

[23]  D. R. Cooper,et al.  Ex vivo removal of serum igg in a patient with colon carcinoma.Some biochemical, immunological and histological observations , 1978, Cancer.

[24]  T. Yamamoto,et al.  Preliminary observations of the effects on breast adenocarcinoma of plasma perfused over immobilized protein A. , 1981, The New England journal of medicine.

[25]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.

[26]  W. Shearer,et al.  Tumoricidal response following perfusion over immobilized protein A: identification of immunoglobulin oligomers in serum after perfusion and their partial characterization. , 1984, Cancer research.

[27]  G. Hennen,et al.  Ex vivo perfusion of plasma over protein A columns in human mammary adenocarcinoma. Role of the Fc‐binding capacity of protein A in the side effects and the tumoricidal response , 1986, European journal of clinical investigation.

[28]  D. Chenoweth,et al.  Induction of interleukin 1 secretion and enhancement of humoral immunity by binding of human C5a to macrophage surface C5a receptors , 1982, The Journal of experimental medicine.

[29]  H. Snyder,et al.  Selective removal of antigen-complexed IgG from cat plasma by adsorption onto a protein A-silica matrix. , 1987, Journal of immunological methods.

[30]  A. Forsgren,et al.  “Protein A” from S. Aureus I. Pseudo-Immune Reaction with Human γ-Globulin , 1966 .

[31]  T. Chang,et al.  Plasma perfused over immobilized protein A for breast cancer. , 1982, The New England journal of medicine.

[32]  W. Arend,et al.  Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. , 1985, Journal of immunology.